Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group

Next Previous
Trial Profile

Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary) ; Desloratadine (Primary) ; Mometasone (Primary) ; Olopatadine (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis; Conjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors ALK-Abello

Most Recent Events

  • 27 Feb 2023 Results assessing the Onset of clinicaleffect was evaluated for grass, ragweed, tree, and house dust mite (HDM)sublingual immunotherapy (SLIT)-tablets from NCT00227279, NCT00783198 and EudraCT2015-004821-15 studies, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 27 Apr 2021 Results of pooled analysis from three trials (2 phase-II/1 phase-III) published in the Allergy
  • 07 Jun 2019 According to ALK Abello media release, the company received european approval for tree pollen sublingual allergy immunotherapy (SLIT) tablet against allergic rhinitis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top